HIV serostatus and tumor differentiation among patients with cervical cancer at Bugando Medical Centre

BMC Research Notes

Nestory Masalu¹  Anthony Massinde³  Peter Rambau²  Moke Magoma³  Dismas Matovelo³ 

[1] Department of Oncology, Bugando Medical Centre, P.O. Box 1370, Mwanza, Tanzania;Department of Pathology, Catholic University of health and allied sciences, P.O. Box 1464, Mwanza, Tanzania;Department of Obstetrics & Gynecology, Bugando Medical Centre, P.O. Box 1370, Mwanza, Tanzania

关键词: Tanzania;    Tumor differentiation;    Clinical stage;    Cervical cancer;    HIV;   

Others  :  1166009
DOI  :  10.1186/1756-0500-5-406

 received in 2011-09-16, accepted in 2012-07-25,  发布年份 2012

【 摘 要 】

Background

Evidence for the association between Human immunodeficiency virus infection and cervical cancer has been contrasting, with some studies reporting increased risk of cervical cancer among HIV positive women while others report no association. Similar evidence from Tanzania is scarce as HIV seroprevalence among cervical cancer patients has not been rigorously evaluated. The purpose of this study was to determine the association between HIV and tumor differentiation among patients with cervical cancer at Bugando Medical Centre and Teaching Hospital in Mwanza, North-Western Tanzania.

Methods

This was a descriptive analytical study involving suspected cervical cancer patients seen at the gynaecology outpatient clinic and in the gynaecological ward from November 2010 to March 2011.

Results

A total of 91 suspected cervical cancer patients were seen during the study period and 74 patients were histologically confirmed with cervical cancer. The mean age of those confirmed of cervical cancer was 50.5 ± 12.5 years. Most patients (39 of the total 74–52.7%) were in early disease stages (stages IA-IIA). HIV infection was diagnosed in 22 (29.7%) patients. On average, HIV positive women with early cervical cancer disease had significantly more CD4+ cells than those with advanced disease (385.8 ± 170.4 95% CI 354.8-516.7 and 266.2 ± 87.5, 95% CI 213.3-319.0 respectively p = 0.042). In a binary logistic regression model, factors associated with HIV seropositivity were ever use of hormonal contraception (OR 5.79 95% CI 1.99-16.83 p = 0.001), aged over 50 years (OR 0.09 95% CI 0.02-0.36 p = 0.001), previous history of STI (OR 3.43 95% CI 1.10-10.80 p = 0.035) and multiple sexual partners OR 5.56 95% CI 1.18-26.25 p = 0.030). Of these factors, only ever use of hormonal contraception was associated with tumor cell differentiation (OR 0.16 95% CI 0.06-0.49 p = 0.001). HIV seropositivity was weakly associated with tumor cell differentiation in an unadjusted analysis (OR 0.21 95% CI 0.04-1.02 p = 0.053), but strong evidence for the association was found after adjusting for ever use of hormonal contraception with approximately six times more likelihood of HIV infection among women with poorly differentiated tumor cells compared to those with moderately and well differentiated cells (OR 5.62 95% CI 1.76-17.94 p = 0.004).

Conclusion

Results from this study setting suggest that HIV is common among cervical cancer patients and that HIV seropositivity may be associated with poor tumour differentiation. Larger studies in this and similar settings with high HIV prevalence and high burden of cervical cancer are required to document this relationship.

【 授权许可】

   
2012 Matovelo et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]WHO/ICO: Tanzania HPV and related cancers. WHO ICO HPV Information Centre; 2010:13-23.
• [2]Wabinga H, Ramanakumar A, Banura C: Survival of cervical cancer patients in Kampala. Uganda. British Journal Of cancer 2003, 89:65-69.
• [3]Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of the 25 major cancers in 1990. Int J Cancer 1999, 80:827-841.
• [4]Sasco A, Jaquet JA, Boidin E: The challenges of AIDS-related malignancies in sub-Saharan Africa. PLoS One 2010, 5(1):e8621.
• [5]Mosha D, Mahande M, Ahaz J: Factors associated with management of cervical cancer patients at KCMC Hospital, Tanzania: a retrospective cross-sectional study. Tanzania Journal of Health Research 2009, 11(2):70-74.
• [6]Syrjanen K: New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors. Eur J Gynaecol Oncol 2008, 29(3):205-221.
• [7]Were E, Nyaberi Z, Buziba N: Integrating cervical cancer and genital tract infection screening into mother, child health and family planning clinics in Eldoret, Kenya. Afr Health sci 2010, 10(1):58-65.
• [8]Strickler HD, Burk R, Fazzari M, et al.: Natural history and possible reactivation of HPV in HIV positive women. Journal of National Cancer Institute 2005, 97:577-586.
• [9]Bosch FX, Lorincz A, Muñoz N: The causal relation between HPV and cervical cancer. J Clin Pathol 2002, 55:244-265.
• [10]Palefsky J: Biology of HPV in HIV infection. Adv Dent Res 2006, 19:99-105.
• [11]Hawes SE, Critchlow C, Sow PS, et al.: Incident high-grade squamous intraepithelial lesions in Senegalese women with and without HIV type 1 (HIV-1) and HIV-2. J Natl Cancer Inst 2006, 98:100-109.
• [12]Serraino D, Dal Maso L, La Vecchia C: Invasive cervical cancer as an AIDS-defining illness in Europe. AIDS 2002, 16:781-786.
• [13]Gichangi P, Vuyst H, Estambale B: HIV and cervical cancer in Kenya. Int J Gynae & Obstet 2002, 76:55-63.
• [14]Bugando Medical Centre: Annual Report. 2009. Mwanza, Tanzania. (unpublished)
• [15]Lyamuya EF, Aboud S, Urassa W: Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, Tanzania. BMC Infect Dis 2009., 9(19)
• [16]Gichangi P, Bwayo J: Impact of HIV infection on invasive cervical cancer in Kenyan women. AIDS 2003, 17(13):1963-8.
• [17]Lomalisa P, Smith T, Guidozzi F: Human Immunodeficiency virus infection and invasive cervical cancer in South Africa. Gynecol Oncol 2000, 77:460-463.
• [18]Nair MS, Bhandari H, Nordin AJ: Cervical cancer in women aged less than 25: East Kent experience. Journal of Obstetrics & Gynecology 2007, 27(7):706-8.
• [19]Abdul MA, Mohamed A, Mayun A: Non-squamous cell carcinoma of the cervix in Zaria, Northern Nigeria: A clinic-pathological Analysis. Annals of African Medicine 2006, 5(3):118-21.